Stocktoria
CareDx, Inc. CDNA
CareDx, Inc. (CDNA) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $379.8M at a -5.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.405 |
| Retained earnings / assets | -1.498 |
| EBIT / assets | -0.074 |
| Equity / liabilities | 2.752 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CDNA | CareDx, Inc. | 4/9 | 0.16 | — | +13.8% |
| CSTL | CASTLE BIOSCIENCES INC | 3/9 | 6.15 | — | +3.7% |
| FLGT | Fulgent Genetics, Inc. | 3/9 | 14.37 | — | +13.8% |
| BLLN | BillionToOne, Inc. | 7/9 | 7.37 | 729.2 | +100% |
| VCYT | VERACYTE, INC. | 7/9 | 15.66 | 61.2 | +16% |
| GRAL | GRAIL, Inc. | 4/9 | -2.86 | — | +17.2% |
| BDSX | BIODESIX INC | 3/9 | -19.59 | — | +24.1% |
About CareDx, Inc.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
FAQ
Is CDNA financially healthy?
CareDx, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CDNA pay a dividend?
No, CareDx, Inc. does not currently pay a dividend.
How profitable is CDNA?
In FY2025, CareDx, Inc. had a net margin of -5.6% and a return on equity of -7.0%.
What is the analyst price target for CDNA?
The average Wall-Street price target for CareDx, Inc. is $25.80, about 45.5% below the recent price, from 5 analysts (consensus: buy).
Is CDNA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CareDx, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.